ENHERTU® Demonstrated Clinically Meaningful and Durable

Daiichi Sankyo and AstraZeneca’s ENHERTU showed an objective response rate of 37.1% in the overall population of the DESTINY-PanTumor02 phase 2 trial



ENHERTU is the first therapy to show... | June 5, 2023

Related Keywords

Texas , United States , Japan , Israel , American , America , Cristian Massacesi , Daiichi Sankyo , Mark Rutstein , Nasdaq , Department Of Investigational Cancer Therapeutics , Clinical Development Program , University Of Texas Md Anderson Cancer Center , Oncology Development , Sarah Cannon Research Institute , Daiichi Sankyo Inc , American Society Of Clinical Oncology , Astrazeneca , Clinical Oncology , Funda Meric Bernstam , Investigational Cancer Therapeutics , Cancer Center , Principal Investigator , Global Head , Chief Medical Officer , Oncology Chief Development Officer , Investigator Assessed , Sarah Cannon Research , Lung Disease , Breast Cancer , Metastatic Gastric Cancer , Absolute Neutrophil Count , Fetal Toxicity , Adverse Reactions , Positive Metastatic Breast Cancer , Low Metastatic Breast Cancer , Reproductive Potential , Hepatic Impairment , Prescribing Information , Daiichi Sankyo Co , Td Stock Exchange , News , Information , Press Release , Daiichi , Sankyo , End , Enhertu , Howed , N , Objective , Response , Gate , F , The , Verall , Population , Hase , , Us , First , Therapy , O 4568 Jp3475350009 ,